NEW YORK (GenomeWeb) – GenMark Diagnostics reported after the close of the market on Thursday that its third quarter revenues rose 7 percent year over year, driven by strength in sales of its eSensor XT-8 and ePlex molecular diagnostics systems.

For the three months ended Sept. 30, the firm reported revenues of $11.6 million, up from $10.8 million a year ago, but short of the consensus Wall Street estimate of $14.6 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.